[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Leonabio Inc (LONA)

Leonabio Inc (LONA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,851
  • Shares Outstanding, K 9,394
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,610 K
  • EBIT $ -34 M
  • EBITDA $ -34 M
  • 60-Month Beta 1.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.30
  • Growth Rate Est. (year over year) +43,534.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.76 +20.88%
on 04/24/26
12.47 -24.78%
on 04/06/26
-1.97 (-17.36%)
since 04/02/26
3-Month
4.21 +122.80%
on 02/13/26
14.21 -33.99%
on 03/18/26
+4.66 (+98.73%)
since 02/04/26
52-Week
2.30 +307.83%
on 05/07/25
14.21 -33.99%
on 03/18/26
+6.50 (+225.69%)
since 05/02/25

Most Recent Stories

More News
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Management to be Joined by Two Clinical Leaders in the Breast Cancer Field  Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer...

LONA : 9.38 (+6.35%)
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...

LONA : 9.38 (+6.35%)
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients...

LONA : 9.38 (+6.35%)
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc.  (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...

LONA : 9.38 (+6.35%)
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with...

ATHA : 6.75 (-6.12%)
LONA : 9.38 (+6.35%)

Business Summary

LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105....

See More

Key Turning Points

3rd Resistance Point 10.03
2nd Resistance Point 9.56
1st Resistance Point 9.19
Last Price 9.38
1st Support Level 8.34
2nd Support Level 7.87
3rd Support Level 7.50

See More

52-Week High 14.21
Fibonacci 61.8% 9.66
Last Price 9.38
Fibonacci 50% 8.26
Fibonacci 38.2% 6.85
52-Week Low 2.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.